Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients & provides custom-made solutions.

Virtual Booth

Contact Supplier

AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

DEVELOPMENTS

1 Drugs in Development

1 Drugs in Development

DIGITAL CONTENT

2 NEWS #PharmaBuzz

media
2 NEWS #PharmaBuzz

Synopsis

ACTIVE PHARMA INGREDIENTS

API Suppliers

USDMF

CEP/COS

JDMF

EU WC

KDMF

NDC API

VMF

Listed Suppliers

API REF. PRICE (USD/KG)

$ 0

MARKET PLACE

API

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

FDF Dossiers

FDA Orange Book

Europe

Canada

Australia

South Africa

Listed Dossiers

1DRUGS IN DEVELOPMENT

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

EDQM

USP

Others

PATENTS & EXCLUSIVITIES

US Patents

US Exclusivities

Health Canada Patents

DIGITAL CONTENT

Data Compilation #PharmaFlow

Stock Recap #PipelineProspector

Weekly News Recap #Phispers

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid (USD)

Annual Reports (USD Million)

Finished Drug Prices

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown

Click the button for full data set

Also known as: Ibiglustat, 1401090-53-6, Genz-682452, Sar402671, Gz/sar402671, Genz-682452-aa

Molecular Formula

C₂₀H₂₄FN₃O₂S

Molecular Weight

389.5 g/mol

InChI Key

YFHRCLAKZBDRHN-MRXNPFEDSA-N

FDA UNII

BLP1XA3FZA

Venglustat is under investigation in clinical trial NCT01674036 (Safety, Tolerability and Pharmacokinetics of Genz-682452 in Healthy Men).

1 2D Structure

Venglustat

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

[(3S)-1-azabicyclo[2.2.2]octan-3-yl] N-[2-[2-(4-fluorophenyl)-1,3-thiazol-4-yl]propan-2-yl]carbamate

2.1.2 InChI

InChI=1S/C20H24FN3O2S/c1-20(2,17-12-27-18(22-17)14-3-5-15(21)6-4-14)23-19(25)26-16-11-24-9-7-13(16)8-10-24/h3-6,12-13,16H,7-11H2,1-2H3,(H,23,25)/t16-/m1/s1

2.1.3 InChI Key

YFHRCLAKZBDRHN-MRXNPFEDSA-N

2.1.4 Canonical SMILES

CC(C)(C1=CSC(=N1)C2=CC=C(C=C2)F)NC(=O)OC3CN4CCC3CC4

2.1.5 Isomeric SMILES

CC(C)(C1=CSC(=N1)C2=CC=C(C=C2)F)NC(=O)O[C@@H]3CN4CCC3CC4

2.2 Other Identifiers

2.2.1 UNII

BLP1XA3FZA

2.3 Synonyms

2.3.1 MeSH Synonyms

1. Genz-682452

2. Gz-sar402671

3. Ibiglustat

2.3.2 Depositor-Supplied Synonyms

1. Ibiglustat

2. 1401090-53-6

3. Genz-682452

4. Sar402671

5. Gz/sar402671

6. Genz-682452-aa

7. Venglustat [usan]

8. Gz402671

9. Blp1xa3fza

10. (s)-quinuclidin-3-yl (2-(2-(4-fluorophenyl)thiazol-4-yl)propan-2-yl)carbamate

11. Sar-402671

12. [(3s)-1-azabicyclo[2.2.2]octan-3-yl] N-[2-[2-(4-fluorophenyl)-1,3-thiazol-4-yl]propan-2-yl]carbamate

13. Gz-402671

14. (3s)-1-azabicyclo(2.2.2)octan-3-yl N-(2-(2-(4-fluorophenyl)-1,3-thiazol-4-yl)propan-2-yl)carbamate

15. Carbamic Acid, N-(1-(2-(4-fluorophenyl)-4-thiazolyl)-1-methylethyl)-, (3s)-1-azabicyclo(2.2.2)oct-3-yl Ester

16. Carbamic Acid, N-[1-[2-(4-fluorophenyl)-4-thiazolyl]-1-methylethyl]-, (3s)-1-azabicyclo[2.2.2]oct-3-yl Ester

17. Ibiglustat [inn]

18. Unii-blp1xa3fza

19. Venglustat [inn]

20. Venglustat (usan/inn)

21. Ibiglustat(genz-682452

22. Venglustat [who-dd]

23. Chembl4297611

24. Schembl12615329

25. Gtpl11550

26. Gz/sar-402671

27. Amy19519

28. Bgc09053

29. Ex-a1870

30. Mfcd28502073

31. Who 10063

32. Akos027337125

33. Zinc202143443

34. Cs-6512

35. Db14966

36. Ac-35551

37. As-52367

38. Hy-16743

39. D11633

40. P14969

41. Q27274745

42. (s)-quinuclidin-3-yl 2-(2-(4-fluorophenyl)thiazol-4-yl)propan-2-ylcarbamate

43. (s)-quinuclidin-3-yl(2-(2-(4-fluorophenyl)thiazol-4-yl)propan-2-yl)carbamate

2.4 Create Date

2012-10-08

3 Chemical and Physical Properties

Molecular Formula	C₂₀H₂₄FN₃O₂S
Molecular Weight	389.5 g/mol
XLogP3	3.5
Hydrogen Bond Donor Count	1
Hydrogen Bond Acceptor Count	6
Rotatable Bond Count	5
Exact Mass	389.15732635 g/mol
Monoisotopic Mass	389.15732635 g/mol
Topological Polar Surface Area	82.7 Å²
Heavy Atom Count	27
Formal Charge	0
Complexity	533
Isotope Atom Count	0
Defined Atom Stereocenter Count	1
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	1

4 Drug and Medication Information

4.1 Drug Indication

Treatment of polycystic kidney disease

Treatment of Parkinson's disease

Treatment of autosomal dominant polycystic kidney disease

Treatment of galactosialidosis, Treatment of GM1 gangliosidosis, Treatment of GM2 gangliosidosis, Treatment of sialidosis

5 Pharmacology and Biochemistry

5.1 MeSH Pharmacological Classification

Enzyme Inhibitors

Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (See all compounds classified as Enzyme Inhibitors.)

Drugs in Development